EpimAb Biotherapeutics Entered into a License Agreement with Almirall to Develop Bispecific Antibody
- EpimAb is eligible to receive ~$210M in milestones upon launch and commercial success of multiple products along with royalties on net sales for any commercialized product. The companies collaborated to develop bispecific Abs for up to three undisclosed target pairs
- Under the terms of the agreement, Almirall to get the rights to use EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform technology to generate, develop, and commercialize bispecific Ab
- The platform helps to generate bispecific Ab & uses the basic structural parts of mAb without adding any complex changes along with patented in all major markets of the world
Ref: Business wire | Image: EpimAb
Related News:- Simcere Entered into an Exclusive License Agreement with Almirall for SIM0278 to Treat Autoimmune Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
